« Previous
Next »
Journal of Oral and Maxillofacial Surgery
Volume 63, Issue 11
, Pages 1567-1575
, November 2005
Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment
References
- . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws (A growing epidemic) . J Oral Maxillofac Surg . 2003;61:1115
-
.
Bisphosphonates and oral cavity avascular bone necrosis
(J Clin Oncol)
. 2003;21:4253
- . Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases . J Oral Maxillofac Surg . 2004;62:527
- . Bisphosphonates and avascular necrosis of the jaw . Aust Dent J . 2003;48:268
-
.
Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates
(A retrospective study)
.
Proc Am Soc Clin Oncol
. 2004;22:750;
(abstr)
-
.
Bisphosphonates–Mechanism of action. Experimental and clinical pharmacology
.
Auctr Preser
. 2000;23:130
- . Osteoradionecrosis–A new concept of its pathophysiology . J Oral Maxillofac Surg . 1983;41:351
- . Studies in the radiobiology of osteoradionecrosis and their clinical significance . Oral Surg Oral Med Oral Pathol . 1987;64:379
- Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosis . Am J Med . 1985;79:596
-
High prevalence of osteonecrosis of the femoral head in HIV-infected adults
.
Ann Intern Med
. 2002;137:17
-
.
Osteonecrosis in patients with SLE
.
Clin Reo Allergy Immunol
. 2003;25:13
-
Thrombophillis and hypofibrinolysis
.
In:
Urbaniak RJ
, Jones JP
editor.
Reversible Pathogenetic Etiologies of Osteonecrosis in Osteonecrosis
(Etiology, Diagnosis and Treatment)
. Rosemont, IL: American Academy of Orthopedic Surgeons; 2001;p. 105–110
- . Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells (The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates or osteoclast precursors) . Bone . 2002;30:64
-
Cellular and molecular mechanisms of action of bisphosphonates
(Skeletal complications of malignancy)
.
Cancer Suppl
. 2000;88:2961
- Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases . N Engl J Med . 1996;335:1785
- Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma . N Engl J Med . 1996;334:488
- Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats . Cancer Res . 2002;62:6538
-
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid
.
J Pharm Exp Thesopuctus
. 2002;302:1055
-
Thalidomide is an inhibitor of angiogenesis
.
Natl Acad Sci U S A
. 1994;91:4082
-
Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnovers by penicillamine and the depletion of capper, an angiogenic cofactor
.
Am J Pathol
. 1990;134:1121
- Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a . Pediatrics . 1999;103:1145
- Endostatin, an endogenous inhibitor of angiogenesis and tumor growth . Cell . 1997;88:277
-
PS-341 (Bortazomib) is active in multiple myeloma. Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies
.
Blood
. 2000;96:516a;
(abstr)
- A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer . Cancer Res . 1997;57:1329
- Bisphosphonate-induced osteopetrosis . N Engl J Med . 2003;349:457
- . Osteonecrosis of the jaw associated with cancer chemotherapy . J Oral Maxillofac Surg . 2004;62:91
PII: S0278-2391(05)01187-0
doi: 10.1016/j.joms.2005.07.010
© 2005 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of Oral and Maxillofacial Surgery
Volume 63, Issue 11
, Pages 1567-1575
, November 2005
